FREE Living Hulled HEMP Seed and Oil Trial
Mo kle
Abstrè
Deskripsyon
The trial will be a 4 week double-blinded, randomized, cross-over design with 2 treatment intervention (hemp and control) periods separated by a 4 week washout period. Thirty metabolically healthy overweight volunteers will be recruited into the trial.
On day 1, and 27, 28 of each treatment period participants will be asked to come to the Richardson Center for Functional Foods and Nutraceuticals (RCFFN) for a 12 hour fasted blood sample. On day 1, participants will be given prepackaged sachets of treatment hulled seeds (hemp or sesame) and salad dressing, containing 30 g/d of treatment (hemp or soybean) oil (in individually packaged daily containers) will also be supplied.
Participants will be instructed by clinical coordinators to integrate the products (2 sachets of seeds, 1 salad dressing) into their daily meals and to avoid other dietary sources of n-3 fatty acids, such as flax, chia, camelina, krill and fish products. Participants will be given activity monitors to wear during the intervention periods. Participants will be required to eat one sachet of hulled seeds in the morning and one in the evening, and to consume the dressing throughout the day, for each 4 week treatment period.
Participants will be asked to continue their habitual diets, while avoiding large dietary sources of n-3 fatty acids, throughout the treatment and washout periods. Participants will be instructed to maintain the same level of physical activity and alcohol intake throughout the trial period. The trial coordinator will contact participants weekly via telephone or email to monitor treatment adherence and to answer any questions or concerns participants might have. Background dietary intakes will be measured at day 1 of the trial using a food frequency questionnaire, and during each treatment period by 3-day food record to be completed in the last week of each treatment period. Participants will be asked questions about the interventions including side effects, mood and perceived energy level by trial coordinators at the end of each intervention period.
Dat
| Dènye verifye: | 08/31/2017 |
| Premye Soumèt: | 03/22/2015 |
| Enskripsyon Estimasyon Soumèt: | 03/24/2015 |
| Premye afiche: | 03/25/2015 |
| Dènye Mizajou Soumèt: | 01/22/2020 |
| Dènye Mizajou afiche: | 01/26/2020 |
| Dat aktyèl kòmanse etid la: | 07/31/2015 |
| Dat Estimasyon Prensipal Estimasyon an: | 01/31/2016 |
| Dat estime fini etid la: | 08/31/2017 |
Kondisyon oswa maladi
Entèvansyon / tretman
Other: Control
Other: Hemp foods
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Active Comparator: Control 54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day | Other: Control |
| Experimental: Hemp foods 60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day | Other: Hemp foods |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | All |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: - Metabolically healthy overweight (BMI 25-35 kg/m2) participants aged 18-65, - Men and women with the ability to give written informed consent and comply with trial guidelines. Exclusion Criteria: - Pregnancy or lactation - Smokers (tobacco products for the last 6 months) - History of cancer, rheumatoid arthritis, chronic illness, cardiovascular problems, liver and kidney disease, inflammatory bowel disease, pancreatitis, gallbladder or biliary disease, neurological/psychological disease, bleeding disorders, experienced platelet abnormalities, and gastrointestinal disorders that could interfere with fat absorption, serum glucose over ≥6.1 mmol/L, serum triglycerides (TG) >4.52 mmol/L, and/or LDL cholesterol (LDL-C) ≥6.5 mmol/L, hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg), - Body mass index (BMI; in kg/m2) ≥35 - Consume or plan to consume anticoagulant, - Hypertension or lipid lowering medications, or hypotensive - Lipid lowering or n-3 PUFA dietary supplements - Reported consumption of more than 2 alcoholic drinks/day or history of alcoholism or drug dependence - Reported use of any experimental medication within 1 month prior to starting the trial. |
Rezilta
Mezi Rezilta Prensipal yo
1. Change in red blood cell omega-3 fatty acid content [Baseline (Day 1) and Endpoint (Day 27,28) of each experimental period]
Mezi Rezilta Segondè
1. Change in plasma lipids [Baseline (Day 1) and Endpoint (Day 27,28) of each experimental period]
2. Change in inflammatory and endothelial function biomarkers [Baseline (Day 1) and Endpoint (Day 27,28) of each experimental period]
3. Change in blood pressure and arterial stiffness [Baseline (Day 1) and Endpoint (Day 27,28) of each experimental period]
4. Change in glucose metabolism and insulin sensitivity [Baseline (Day 1) and Endpoint (Day 27,28) of each experimental period]
Lòt Mezi Rezilta
1. Change in body composition [Measurements will be done at the beginning and end of each of the two 4-week treatment]
2. Physical activity [from day 20-28 of each treatment period]
